Ford Megan M - OmicsDI

Previous page
1 / 2
You're on page 1
page 2
Next page

Sort by:

Relevance

Page size

Gene expression profiling of invasive breast cancer events from the tamoxifen prevention trial

Gene expression profiling of invasive breast cancer events from the tamoxifen prevention trial validates low estrogen receptor mRNA level as the main determinant of tamoxifen resistance in estrogen receptor positive breast cancer. In NSABP Breast Cancer Prevention Trial (BCPT), tamoxifen reduced th...

ORGANISM(S): Homo sapiens

2011-12-08 | E-GEOD-12665 | biostudies-arrayexpress

Metabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target

The genomic landscape of colorectal cancer (CRC) is shaped by inactivating mutations in tumour suppressors such as APC, and oncogenic mutations such as mutant KRAS. Here we used genetically engineered mouse models (GEMMs), and multimodal mass spectrometry-based metabolomics to study the impact of co...

ORGANISM(S): Homo Sapiens (ncbitaxon:9606) Mus Musculus (ncbitaxon:10090)

2023-07-18 | MSV000092468 | MassIVE

GNPS - Metabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target

ORGANISM(S): Homo Sapiens (ncbitaxon:9606) Mus Musculus (ncbitaxon:10090)

2023-07-18 | MSV000092468 | GNPS

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Not available

S-EPMC7884931 | biostudies-literature

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Not available

S-EPMC10957483 | biostudies-literature

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.